This study will assess the safety and efficacy of FA Intravitreal Inserts in subjects with macular edema secondary to RVO.

Inclusion Criteria:

• Diagnosis of macular edema due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)
• Central subfield thickness > 300 μm
• BCVA of ≥ 24 and ≤ 68 letters
• Males and non-pregnant females 18 years and over

Exclusion Criteria:

• Macular edema secondary to any condition other than RVO
• Presence of foveal atrophy, dense pigmentary changes or dense subfoveal exudates in the study eye
• Cystic intraretinal hemorrhage involving the fovea in the study eye that is responsible for vision loss
• Glaucoma or ocular hypertension (IOP > 21 mmHg or concurrent therapy at screening with IOP-lowering agents)
• Any prior treatment with intravitreal, subtenon, or periocular steroid or anti-VEGF therapy since the diagnosis of RVO in the study eye
• Any change in systemic steroid therapy within 3 months of screening
• History of vitrectomy in the study eye